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Summary
Objective—To determine the incidence of meningitis caused by Haemophilus influenzae, 
Neisseria meningitidis, and Streptococcus pneumoniae in the North American Arctic during 2000–
2010.
Methods—Surveillance data were obtained from the International Circumpolar Surveillance 
network. We defined a case of bacterial meningitis caused by H. influenzae, N. meningitidis, or S. 
pneumoniae as a culture-positive isolate obtained from a normally sterile site in a resident with a 
meningitis diagnosis.
Results—The annual incidence/100,000 persons for meningitis caused by H. influenzae, N. 
meningitidis, and S. pneumoniae among all North American Arctic residents was: 0.6, 0.5, and 
1.5, respectively; the meningitis incidence among indigenous persons in Alaska and Canada 
(indigenous status not recorded in Greenland) for those three bacteria was: 2.1, 0.8, and 2.4, 
respectively. The percentage of pneumococcal isolates belonging to a 7-valent pneumococcal 
conjugate vaccine serotype declined from 2000–2004 to 2005–2010 (31% to 2%, p-value <0.01). 
During 2005–2010, serotype a caused 55% of H. influenzae meningitis and serogroup B caused 
86% of meningococcal meningitis.
Conclusions—Compared with all North American Arctic residents, indigenous people suffer 
disproportionately from bacterial meningitis. Arctic residents could benefit from the development 
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of a H. influenzae serotype a vaccine and implementation of a meningococcal serogroup B 
vaccine.
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INTRODUCTION
Historically, populations in the Arctic region of North America, especially indigenous 
people, have suffered disproportionately from bacterial meningitis compared with non-
Arctic populations in the United States and Canada. During 1978–81, the annual incidence 
of bacterial meningitis in the overall U.S. population was 3/100,000 persons overall and the 
highest rates were observed among infants aged <1 year (77/100,000 persons).(1) By 
comparison, the annual incidence of bacterial meningitis among Alaska Native people in 
southwest Alaska during 1971–74 was 94/100,000 persons overall and 3,242/100,000 
among infants aged <1 year.(2) In Northern Canada, the annual bacterial meningitis 
incidence during 1972–77 was 19/100,000 persons among non-indigenous residents 
compared with 200/100,000 among indigenous people.(3) Conjugate vaccines to protect 
against certain serotypes/serogroups of Haemophilus influenzae, Neisseria meningitidis, and 
Streptococcus pneumoniae, three common causes of bacterial meningitis, are now available 
and part of routine childhood immunization schedules. (See Table 1 for the specific years 
that the North American Arctic regions implemented these vaccines). Since the introduction 
of those vaccines, however, the incidence of meningitis in Arctic populations has not been 
reevaluated.
Populations in Alaska, Northern Canada, and Greenland share certain unique social and 
environmental risk factors for infectious diseases.(4) The Arctic region is sparsely populated 
with limited health care/public health infrastructure.(5) The risk for infectious diseases is not 
uniform within North American Arctic populations. In particular, indigenous people (e.g., 
Eskimo people in Alaska and Inuit people of Greenland, Northern Canada, and Alaska), who 
comprise varying proportions of the population in each region (Table 1), experience a 
greater burden of infectious diseases compared with non-indigenous people.(3, 6) 
Indigenous people are at higher risk for infectious diseases than non-indigenous people 
because they have greater exposure to conditions that facilitate disease transmission such as 
household crowding and inadequate access to water/sanitation services.(7, 8) In order to 
better understand the distinct epidemiology of infectious diseases in the Arctic that result 
from these risk factors, public health agencies in countries with populations residing in the 
Arctic collaboratively operate the International Circumpolar Surveillance (ICS) network.(9) 
ICS methods allow participating countries to use existing infrastructure to collect and share 
public health surveillance data.(5) All three North American countries with Arctic 
populations – United States, Canada, and Greenland – participate in ICS and have shared 
surveillance data for certain invasive bacterial diseases since 2000.(6) This study uses ICS 
data to describe the epidemiology of meningitis caused by S. pneumoniae, H. influenzae, and 
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ICS defines a case of bacterial meningitis caused by H. influenzae, N. meningitidis, or S. 
pneumoniae as a culture-positive isolate obtained from a normally sterile site (e.g., blood, 
cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid) in a resident of the 
surveillance areas with a diagnosis of meningitis recorded in their medical record. Case-
isolates were identified through population-based surveillance by 52 participating 
laboratories (23 in Alaska, 14 in Northern Canada [Yukon, Northwest Territories and 
Nunavut], 15 in Greenland).(5) Laboratories reported case-patients to public health 
personnel and forwarded sterile site specimens to regional reference laboratories for 
additional testing to confirm organism identity and to determine serotype/serogroup. Public 
health personnel obtained case-patients’ demographic characteristics, clinical characteristics, 
risk factor information, and immunization history from reviewing their medical records. 
These epidemiologic data were recorded on a standard, organism-specific data collection 
form.
The reference laboratories confirm the identity of S. pneumoniae, H. influenzae, or N. 
meningitidis by colony morphology/biochemical characteristics using standard laboratory 
methods (10); however, methods used for determining serotype/serogroup are not uniform 
across reference laboratories so an interlaboratory quality control program exists to ensure 
comparability of results.(11, 12) The methods for determining serotype/serogroup have been 
described previously.(11, 12) For S. pneumoniae, serotype testing was done in all three 
regions by the Quellung reaction.(13) H. influenzae serotype testing was performed by either 
slide agglutination or polymerase chain reaction capsule typing; some laboratories employed 
both methods. N. meningitidis serogroup testing was performed by slide agglutination, latex 
agglutination together with staphylococcal coagglutination, or polymerase chain reaction; 
some laboratories employed more than one method.
Additionally, the reference laboratories performed antibiotic susceptibility testing on S. 
pneumoniae isolates. Antibiotic susceptibility testing was performed by the broth 
microdilution method in Alaska and Northern Canada and by Etest (AB Biodisk, Solna, 
Sweden) for isolates from Greenland.(11) Antibiotics tested included penicillin, third 
generation cephalosporins (cefotaxime and ceftriaxone), chloramphenicol, clindamycin, 
erythromycin, fluoroquinolones (ofloxacin and levofloxacin), trimethoprim-
sulfamethoxazole, and vancomycin. Per ICS protocol, minimal inhibitory concentrations 
(MICs) were interpreted according to Clinical and Laboratory Standards Institute standards 
for parenteral nonmeningitis treatment.(14)
Data Analysis
Epidemiologic and laboratory data from the ICS countries were forwarded annually to an 
ICS coordinator in Anchorage, Alaska. All data were double entered into Paradox version 
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10.0 (Corel, Ottawa, Ontario, Canada) and analyzed by using SAS version 9.3 (SAS 
Institute, Cary, NC, USA). Population estimates for incidence calculations were obtained 
from Statistics Canada website (www.statcan.ca), the Alaska Department of Labor and 
Workforce Development website (www.labor.state.ak.us), and the Statistics Greenland 
website (www.statgreen.gl). Census data from Alaska and Canada indicate whether persons 
belong to an indigenous group. Census data from Greenland do not indicate the indigenous 
status of persons; therefore, case-patients from Greenland were excluded from analyses by 
indigenous status. Crude incidence and 95% confidence interval (CI) were calculated by 
assuming a Poisson distribution. Age-adjusted incidence rates were calculated by using the 
World Health Organization 2000 standard population and the age groups of <1, 2–19, 20–
64, and >65 years.
RESULTS
Descriptive Epidemiology
We identified 247 meningitis cases in the North American Arctic during our study period 
(Figure 1). Of those cases, 139 were caused by S. pneumoniae (median: 12/year; range: 9–
16/year), 58 by H. influenzae (median: 5/year; range: 3–8/year), and 50 by N. meningitidis 
(median: 5/year; range: 1–8/year). By ICS region, 141 cases occurred in Alaska (median: 12/
year; range: 5–20/year), 74 in Northern Canada (median: 6/year; range: 4–10/year), and 32 
in Greenland (median: 3/year; range: 0–6/year). No cases of H. influenzae meningitis were 
detected in Greenland. Of the 58 H. influenzae cases, 30 were caused by serotype a (21 cases 
in Northern Canada and 9 cases in Alaska).
Meningitis case-patients were younger in Northern Canada (median age: 0.8 years) 
compared with Alaska (median age: 17.3 years) and Greenland (median age: 36.6 years) 
(Table 2). Case-patients infected with S. pneumoniae, the most common cause of meningitis 
among the three organisms evaluated, were older in Alaska (median age: 38.3 years) and 
Greenland (median age: 46.2 years) than in Northern Canada (median age: 1.2 years). 
Meningitis case-patients infected with N. meningitidis were also older in Alaska (median 
age: 12.6 years) and Greenland (median age: 5.6 years) compared with Northern Canada 
(median age: 1.8 years). Case-patients with H. influenzae were young in Alaska (median 
age: 0.8 years) and Northern Canada (median age: 0.5 years). Among case-patients infected 
with H. influenzae, 83% were aged <2 years compared with 32% and 31% of case-patients 
infected with S. pneumoniae and N. meningitidis, respectively. Meningitis case-patients 
were more likely to be indigenous in Northern Canada (86%) than in Alaska (43%). Among 
case-patients with H. influenzae meningitis whose indigenous status was known, 30 persons 
(68%) in Northern Canada and 17 persons (97%) in Alaska were indigenous (data not 
shown). Almost all meningitis case-patients were hospitalized. A total of 20 (14%), 6 (9%), 
and 6 (21%) case-patients from Alaska, Northern Canada, and Greenland, respectively, died. 
Meningitis in case-patients was most frequently associated with pneumonia, followed by 
cellulitis, endocarditis, and pericarditis.
Vaccination status was known for 79 case-patients from Alaska and 65 case-patients from 
Northern Canada. Among case-patients with a known vaccination status in Alaska, 62% 
(16/26) of persons aged <17 years with pneumococcal meningitis had received ≥1 dose of a 
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pneumococcal conjugate vaccine, 35% (8/23) of persons aged ≥17 years with pneumococcal 
meningitis had received the 23-valent protein polysaccharide pneumococcal vaccine, and 
83% (15/18) of persons aged <10 years with H. influenzae meningitis had received the H. 
influenzae type b vaccine; 0% (0/12) of case-patients with meningococcal meningitis had 
received the quadrivalent meningococcal conjugate vaccine. Among case-patients with a 
known vaccination status in Northern Canada, 36% (5/14) of person aged <17 years with 
pneumococcal meningitis had received a pneumococcal conjugate vaccine, 18% (2/11) of 
persons aged ≥17 years with pneumococcal meningitis had received the 23-valent protein 
polysaccharide pneumococcal vaccine, and 83% (25/30) of persons aged <10 years with H. 
influenzae meningitis had received the H. influenzae type b vaccine; 38% (3/8) of case-
patients with meningococcal meningitis aged <17 years and 0% (0/2) aged ≥17 years had 
received the quadrivalent meningococcal conjugate vaccine. In Greenland, only the H. 
influenzae serotype b vaccine was used as part of a routine immunization program during 
our study period and no case-patients with H. influenzae meningitis were reported (Table 1).
Incidence Rates
The overall annualized crude incidence of meningitis/100,000 persons caused by S. 
pneumoniae, H. influenzae, and N. meningitidis in the three North American ICS regions 
during our study period was 2.6 (95% CI: 2.3–2.9) and the age-standardized incidence was 
2.7 (Table 3). The overall crude incidence of meningitis among indigenous persons in 
Alaska and Northern Canada was 5.2 (95% CI: 4.3–6.3), among non-indigenous persons in 
Alaska and Northern Canada was 1.5 (95% CI: 1.2–1.8), and among all children aged <2 
years was 34.9 (95% CI: 28.7–42.1). The overall annualized crude incidence of meningitis 
hospitalizations was 2.5 (95% CI: 2.2–2.8) and the age-standardized hospitalization 
incidence was 2.6. The overall annualized crude incidence of meningitis deaths was 0.3 
(95% CI: 0.2–0.5) and the age-standardized death incidence was 0.4.
The annualized crude incidence of meningitis caused by S. pneumoniae, H. influenzae, or N. 
meningitidis in Alaska was 1.9 (95% CI: 1.6–2.3), in Northern Canada was 4.9 (95% CI: 
3.9–6.2), and in Greenland was 5.0 (95% CI: 3.4–7.1) (Table 3). The annualized crude 
incidence of meningitis hospitalizations in Alaska was 1.8 (95% CI: 1.5–2.2), in Northern 
Canada was 4.5 (95% CI: 3.5–5.7), and in Greenland was 5.0 (95% CI: 3.4–7.1). The 
annualized crude incidence of meningitis deaths in Alaska was 0.3 (95% CI: 0.2–0.4), in 
Northern Canada was 0.4 (95% CI: 0.2–0.9), and in Greenland was 1.0 (95% CI: 0.4–2.1).
The annualized crude incidence of meningitis in all three regions caused by S. pneumoniae 
was 1.5 (95% CI: 1.2–1.7), by H. influenzae was 0.6 (95% CI: 0.5–0.8), and by N. 
meningitidis was 0.5 (95% CI: 0.4–0.7) (Table 3). The annualized crude incidence of 
hospitalizations caused by S. pneumoniae was 1.4 (95% CI: 1.2–1.6), by H. influenzae was 
0.6 (95% CI: 0.5–0.8), and by N. meningitidis was 0.5 (95% CI: 0.4–0.6). The overall crude 
incidence of deaths caused by S. pneumoniae was 0.3 (95% CI: 0.2–0.4), by H. influenzae 
was 0.0 (95% CI: 0.0–0.1), and by N. meningitidis was 0.1 (95% CI: 0.0–0.1).
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Serotype Distribution and Antibiotic Resistance
Among case-patients in Alaska, the percentage of pneumococcal isolates belonging to a 
serotype included in the 7-valent pneumococcal conjugate vaccine declined from 2000–2004 
to 2005–2010 (31% to 2%, p-value <0.01) and the percentage belonging to one of the 6 
additional serotypes in the 13-valent pneumococcal conjugate vaccine increased (14% to 
43%, p-value = 0.01) (Table 4). The percentage of pneumococcal isolates belonging to the 
7-valent pneumococcal conjugate vaccine or one of the 6 additional serotypes in the 13-
valent pneumococcal conjugate vaccine did not change between 2000–2004 and 2005–2010 
among persons with meningitis in Northern Canada and Greenland. In Alaska and Northern 
Canada, the percentage of H. influenzae isolates belonging to serotype a or serotype b was 
similar between 2000–2004 and 2005–2010; by 2005–2010, serotype a was the predominant 
cause of H. influenzae meningitis. In all three ICS regions, there was no difference in the 
percentage of meningococcal isolates belonging to a serogroup included in the quadrivalent 
meningococcal vaccine (serogroups A, C, Y, W135) or to serogroup B between 2000–2004 
and 2005–2010; by 2005–2010, the majority of meningococcal meningitis was caused by 
serogroup B.
Pneumococcal isolates susceptibility to penicillin, ceftriaxone, and vancomycin was 77%, 
90%, and 100%, respectively, in Alaska and 86%, 94%, and 100% in Northern Canada 
(Table 5). In Greenland, all pneumococcal isolates were susceptible to the three antibiotics 
tested for in that region (penicillin, ceftriaxone, and erythromycin).
DISCUSSION
Previous studies evaluating the epidemiology of bacterial meningitis in the North American 
Arctic had certain limitations. The incidence estimates from those earlier studies were either 
imprecise (because the populations under surveillance were small) or unrepresentative 
(because the surveillance regions encompassed large populations living outside the Arctic) 
(2, 3, 15). We were able to overcome those limitations by using population-based 
surveillance data from the International Circumpolar Surveillance network to estimate the 
incidence of bacterial meningitis caused by S. pneumoniae, H. influenzae, and N. 
meningitidis in the North American Arctic during 2000–2010.
The meningitis incidence in the North American Arctic is likely much lower now compared 
with historical estimates. In southwest Alaska, the annual incidence of bacterial meningitis 
among children aged <5 years was 474/100,000 during 1971–1974.(2) In northern central 
Canada, the annual incidence of meningitis among all ages during a four-year period in the 
mid-1970s was 128/100,000.(3) Although the estimates of bacterial meningitis from these 
older studies are not directly comparable with our results, the greater than ten-fold 
difference in the magnitude of the incidence increases the possibility that the decline over 
the previous four decades is likely a real trend.
A substantial proportion of the decline in meningitis rates can be attributed to 
implementation of vaccines to protect against H. influenzae serotype b (Table 1), the leading 
cause of bacterial meningitis during the 1970s.(2, 3) Our results indicate that H. influenzae 
meningitis has been virtually eradicated among non-indigenous people in the Arctic. 
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However, the rates among indigenous people in Alaska and Northern Greenland, especially 
children aged <2 years, remain high. The high incidence among indigenous people is partly 
explained by the emergence of H. influenzae serotype a infections in that population. 
Culture-confirmed invasive H. influenzae serotype a isolates were first identified in Alaska 
in 2002,(16) and an increase in H. influenzae serotype a disease has also been observed in 
Canada.(17, 18) According to our results, serotype a is now the predominant cause of H. 
influenzae meningitis in Alaska and Northern Canada. Thus, the development of a new 
vaccine against H. influenzae serotype a could be uniquely beneficial to Arctic residents, 
especially in Alaska and Northern Canada. Additionally, we demonstrated that S. 
pneumoniae is now the leading cause of meningitis in our population. Therefore, we expect 
the incidence of meningitis to decrease with increased coverage of pneumococcal conjugate 
vaccines (Table 1). Similarly, the majority of meningococcal meningitis cases belonged to 
serogroup B and implementation of a vaccine against that serogroup could result in further 
reductions in the incidence of meningitis.
Despite the decline in meningitis incidence, it remains elevated in the North American 
Arctic compared with the general U.S. and Canadian populations. The most recent estimate 
of bacterial meningitis incidence in Canada comes from a retrospective review of all 
hospitalized bacterial meningitis cases during 1994–2001; that study determined an annual 
incidence of 3/100,000.(15) In the United States, the annual incidence of meningitis caused 
by S. pneumoniae, H. influenzae, N. meningitidis, group B streptococcus, or Listeria 
monocytogenes for all ages declined from 2.0/100,000 to 1.4/100,000 over a similar time 
period (1998–2007).(19) The incidence of meningitis caused by S. pneumoniae, H. 
influenzae, and N. meningitidis among non-indigenous people in our study was similar to 
that of the general Canadian and US populations. However, the incidence among indigenous 
people was approximately three-times higher than non-indigenous people. The median age 
of meningitis case-patients was substantially lower in Northern Canada than in Alaska and 
Greenland. The lower age of meningitis case-patients in Northern Canada could be because 
H. influenzae was the predominant cause of meningitis in Northern Canada and the majority 
of case-patients with H. influenzae meningitis were aged <2 years. In contrast, the 
predominant cause of meningitis in Alaska and Greenland was S. pneumoniae and the 
median age for case-patients with pneumococcal meningitis was higher than those with H. 
influenzae meningitis.
The disparity in the incidence of meningitis cases and hospitalization for meningitis between 
indigenous people and non-indigenous people could result from differences in social and 
environmental risk factors. For example, household crowding and inadequate access to in-
home piped water are more common among indigenous than non-indigenous persons;(5) 
these factors have been demonstrated to facilitate transmission of respiratory infections.(8) 
Additionally, indigenous persons are more likely to live in small communities that are 
inaccessible by roads.(5) The geographic isolation of these communities combined with 
limited access to healthcare can be a barrier to identification and provision of prophylactic 
treatment to contacts of persons with H. influenzae and N. meningitidis meningitis to prevent 
secondary meningitis cases.
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Bacterial meningitis is a serious illness with potential to result in neurologic sequelae or 
death if appropriate treatment is delayed.(20) Antibiotic susceptibility data was available to 
us for case-patients with pneumococcal meningitis, the most common cause of meningitis 
among the three bacteria we evaluated. When pneumococcal meningitis is considered, 
treatment guidance for children and adults recommend a third generation cephalosporin for 
empiric therapy; in addition, vancomycin is recommended in Alaska and Canada.(21, 22) 
Our data demonstrates high susceptibility to those antibiotics among pneumococcal isolates 
from meningitis case-patients.
Our study had limitations. First, the small population size in the Arctic resulted in 
insufficient meningitis cases to determine incidence stratified by year, bacterial etiology and 
region. Aggregating by country alone precluded evaluation of the impact of the different 
country vaccine programs (Table 1) on the incidence of meningitis caused by bacterial 
etiology. Similarly, aggregating by bacterial etiology alone masked potential regional 
differences in the incidence of meningitis that result from the unique geography and 
environment of each region. Our study encompassed a broad time period and aggregating 
meningitis cases across all years prevented us from correlating trends in meningitis 
incidence within our study period with other changes such as improvements in sanitation or 
implementation of vaccines. Second, certain ICS data elements were not consistently 
collected across all regions. Information on risk factors for meningitis, such as case-patient’s 
history of immunosuppressing conditions, was not available for many cases. Thus, some of 
the differences in meningitis incidence might be the result of differences in the prevalence of 
those predisposing factors. Also, antibiotic resistance testing was not routinely performed in 
the participating ICS countries for H. influenzae and N. meningitidis. Therefore, we were 
unable to comment on the effectiveness of commonly recommended antibiotics for the 
empiric treatment of bacterial meningitis caused by H. influenzae and N. meningitidis.(21, 
22) Finally, we likely underestimated the meningitis incidence by including only culture-
confirmed cases in our analysis. For example, a patient with bacterial meningitis might not 
be reported to our surveillance system if the sterile site culture was obtained after 
administering antibiotics. Furthermore, any differences between regions in the clinical/
laboratory diagnostic capabilities for bacterial meningitis could have affected our 
comparisons of the incidence.
In this study, we provide updated estimates of the incidence of meningitis in the North 
American Arctic. Although the incidence of meningitis among Arctic people caused by 
these three bacteria has declined in recent decades, we demonstrated that a disparity 
continues to exist between Arctic (especially Indigenous) and non-Arctic populations. Wider 
implementation of vaccines against S. pneumoniae, H. influenzae, and N. meningitidis can 
help address that disparity. Our results provide a basis for determining the future impact of 
the implementation of those vaccines on the incidence of meningitis. Finally, our results can 
inform empiric treatment decisions of providers caring for persons in the Arctic who present 
with suspected bacterial meningitis.
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Table 1
Characteristics of North American Arctic Countries
Alaska Northern Canada Greenland
Populationa 668 662 136 921 56 550
% Indigenous 19% 60% Unknown
Region size, km2 1 518 807 4 506 600 2 131 863
Year vaccine introduced or recommended in regionb
  7-valent pneumococcal conjugate vaccine 2001 2002–2006 N/A
  10-valent pneumococcal conjugate vaccine N/A 2010–2011 N/A
  13-valent pneumococcal conjugate vaccine 2010 2010–2011 2010
  23-valent pneumococcal polysaccharide vaccine 1983 1983 1996
  Quadrivalent meningococcal conjugate vaccine 2006 2005–2006 N/A
  Serogroup C meningococcal conjugate vaccine N/A 2002–2007 N/A
  Haemophilus influenzae serotype b vaccine 1991 1986–1997 1996




Northern Canadian territories introduced vaccines over different time periods.
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Table 2
Demographic and Clinical Characteristics of Meningitis Case-Patients by Country, 2000–2010
Characteristic Alaska Northern Canada Greenland
Number of meningitis case-patients 141 74 32
Number aged <2 years (%)a 48 (34) 52 (70) 9 (28)
Median age (range)a 17.3 (0.2–87.5) 0.8 (0–72) 36.6 (0–70.9)
Number males (%)b 72 (51) 38 (52) 21 (68)
Number indigenous (%)c 61 (43) 59 (86) N/A
Number hospitalized (%)d 135 (96) 68 (96) 32 (100)
Number deaths (%)e 20 (14) 6 (9) 6 (21)
Top 4 associated syndromes
Pneumonia 31 (22) 6 (8) 3 (9)
Cellulitis 4 (3) 3 (4) 0 (0)
Endocarditis 4 (3) 0 (0) 1 (3)
Pericarditis 1 (1) 2 (3) 0 (0)
Abbreviations: N/A, data not available
a
Age unknown for 1 case-patient from Greenland.
b
Sex unknown for 1 case-patient from Northern Canada and 1 case from Greenland.
c
Indigenous status unknown for 5 case-patients from Northern Canada.
d
Hospitalization status unknown for 1 case-patient from Alaska and 3 case-patients from Northern Canada.
e
Death status unknown for 1 case-patient from Alaska, 9 case-patients from Northern Canada, 3 case-patients from Greenland.
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